Lidocaína 5% Braun (Lidocaine Hydrochloride)

Lidocaine blocks voltage‑gated sodium channels on nerve membranes, preventing the rapid influx of sodium ions that initiates an action potential. This inhibition stops nerve impulse propagation, resulting in a reversible loss of sensation in the area where the drug is administered.

The specific dose of Lidocaína 5% Braun is determined by the prescribing clinician based on the procedure, patient weight, age, and clinical condition. Healthcare professionals calculate the appropriate volume to stay within recommended maximum limits and to achieve the desired anesthetic effect.

Safety data for lidocaine use in pregnancy and lactation are limited. It is generally classified as Category B in many regions, indicating that animal studies have not shown risk but human data are insufficient. Use only when the potential benefit justifies any potential risk to the fetus or infant, and always under medical supervision.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain requirements), and necessary import documentation.

The primary alternative to lidocaine is bupivacaine, which has a longer duration of action but a higher risk of cardiotoxicity at comparable doses. Lidocaine offers a faster onset and a shorter, more controllable duration, making it preferable for procedures requiring rapid recovery of sensation. Choice depends on the clinical need for duration versus safety profile.

Lidocaína 5% Braun should be stored at room temperature, below 25 °C, in its original sealed container. Protect the product from direct sunlight, moisture, and extreme temperature fluctuations. Do not freeze. Inspect the solution before use for any particulate matter or discoloration and discard if integrity is compromised.

The product is administered by a qualified healthcare professional via epidural, intramuscular, or intravenous injection, depending on the intended clinical use. The injection site is prepared aseptically, and the volume injected is calculated to stay within safe dosage limits. Continuous monitoring is recommended during and after administration.

Serious risks include central nervous system toxicity (seizures, loss of consciousness), cardiovascular complications (arrhythmias, severe hypotension, cardiac arrest), and allergic reactions such as anaphylaxis. These events are rare but require immediate medical intervention. Monitoring of vital signs and plasma drug levels is essential when high doses are used.

Patients with a known hypersensitivity to lidocaine or other amide‑type local anesthetics should avoid this product. It is also contraindicated in individuals with severe heart block, uncontrolled epilepsy, or significant hepatic impairment that could impair drug metabolism. Clinicians must assess each patient’s medical history before administration.